Xenetic Biosciences, Inc. (XBIO): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:35 ET
- Event date
- 2026-11-13
- Accession no.
- 0001683168-26-008650
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Xenetic reports third quarter 2026 results and updates proposed Santersus acquisition
Xenetic reported a net loss of approximately $1.7 million for the quarter ended September 30, 2026, compared to approximately $0.5 million for the same period in 2025. It also updated its proposed all-stock acquisition of Santersus and reported the first patient dosed in a study combining systemic DNase I with CAR T-cell therapy, with initial efficacy data expected in Q2 2027.
- Royalty revenue decreased approximately 29% to approximately $0.7 million for the three months ended September 30, 2026.
- Quarterly net loss was approximately $1.7 million, or $0.72 per basic and diluted share.
- Cash and cash equivalents totaled approximately $5.8 million as of September 30, 2026.
- The proposed all-stock acquisition of Santersus is expected to close in the first quarter of 2027, subject to approvals and conditions.
earningsmerger acquisitionproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | xenetic_8k.htm |
| EX-99.1 | PRESS RELEASE | xenetic_ex9901.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.